Search results for "CANCER STEM CELL"

showing 10 items of 220 documents

Human Thyroid Cancer Stem Cells

2011

Increasing advances in stem cell research have opened new chances for treatment of many types of cancers. The identification of Cancer Stem Cells (CSCs) will provide a better knowledge of the molecular events governing carcinogenesis and the establishment of more accurate diagnostic methods and effective therapies. Parallel to other tumors, it has been demonstrated the presence of CSCs in thyroid cancers. Here, we will discuss the origin of human thyroid cancer stem cells and what is known about the molecular and the cellular aspects of their biology. We will also explore the potential traits of CSCs in thyroid cancer which give hope for the development of new therapeutic approaches in trea…

Oncologymedicine.medical_specialtyDiagnostic methodsbusiness.industryThyroidmedicine.diseasemedicine.disease_causemedicine.anatomical_structureCancer stem cellInternal medicineCellular aspectsmedicineCancer researchHuman thyroidStem cellCarcinogenesisbusinessThyroid cancer
researchProduct

Analysis of immunosuppressive factors produced by tumorspheres in NSCLC: Prognostic value of galectin-3 in adenocarcinoma

2019

Abstract Background Cancer stem cells (CSCs) are targets poorly recognized by the immune surveillance system given that they induce an immunosuppressive microenvironment. The aim of this work is to study the interactions between CSCs and the immune microenvironment in NSCLC. Methods Tumor cells from 8 resected NSCLC patients and 12 cell lines were established as tumorspheres enriched in CSCs and as monolayers. The gene expression of IL-4, IL-10, IL6, IL8 and LGALS-3 was analyzed by RTqPCR. Results were validated at a protein level by a sensitivity bead-based multiplex immunoassay using the Millipore kit for Luminex 100/200. The prognostic value of these factors in silico was determined in a…

Oncologymedicine.medical_specialtyLungbusiness.industryProportional hazards modelHematologymedicine.diseasemedicine.anatomical_structureOncologyGalectin-3Cancer stem cellInternal medicineGene expressionmedicineAdenocarcinomaInterleukin 8businessSurvival analysisAnnals of Oncology
researchProduct

Survivin is regulated by interleukin-4 in colon cancer stem cells

2010

Colorectal cancer has provided an important model to test the stem cell hypothesis of cancer origin, which implies that cancer arises as a result of genetic aberrations in stem cells leading to deregulation of the proliferation/differentiation balance. We and others have demonstrated that, similarly to other solid tumors, colon carcinogenesis and progression are dictated by highly apoptosis-resistant stem-like cells. Our data have suggested that protection from apoptosis is achieved by autocrine production of interleukin-4 (IL-4) through up-regulation of anti-apoptotic mediators. In this study, we extend our analysis to another apoptosis inhibitor widely expressed in tumors, namely survivin…

Organoplatinum CompoundsPhysiologyColorectal cancerSurvivinmedicine.medical_treatmentClinical BiochemistryFluorescent Antibody TechniqueAntineoplastic AgentsApoptosisBiologyInhibitor of Apoptosis ProteinsSurvivin inetrleukin-4Cancer stem cellSurvivinIn Situ Nick-End LabelingmedicineHumansPhosphorylationAutocrine signallingInterleukin 4Staining and LabelingCancerIsoxazolesCell Biologymedicine.diseaseGene Expression Regulation NeoplasticOxaliplatinProtein TransportCytokineImmunologyNeoplastic Stem CellsCancer researchInterleukin-4Stem cellColorectal NeoplasmsSTAT6 Transcription FactorMicrotubule-Associated ProteinsLeflunomideJournal of Cellular Physiology
researchProduct

miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance

2015

AbstractThe ErbB tyrosine kinase receptor family has been shown to have an important role in tumorigenesis, and the expression of its receptor members is frequently deregulated in many types of solid tumors. Various drugs targeting these receptors have been approved for cancer treatment. Particularly, in breast cancer, anti-Her2/EGFR molecules represent the standard therapy for Her2-positive malignancies. However, in a number of cases, the tumor relapses or progresses thus suggesting that not all cancer cells have been targeted. One possibility is that a subset of cells capable of regenerating the tumor, such as cancer stem cells (CSCs), may not respond to these therapeutic agents. Accumula…

P63cancer stem cellsCancer ResearchReceptor ErbB-2oncogenesmedicine.medical_treatmentmedicine.disease_causeTargeted therapyERBB3Molecular Targeted TherapyDEATHErbB ReceptorsGene Expression Regulation NeoplasticNeoplastic Stem CellsFemaleOriginal Articlemedicine.drugCARCINOMAMIGRATIONCancer Stem Cells; Breast CancerImmunologyBreast NeoplasmsCancer Stem CellMIR-205miR-205-5pBiologyLapatinibcancer treatmentNOCellular and Molecular Neurosciencebreast cancerBreast cancerErbBCancer stem cellCell Line TumormedicineHumansSUPPRESSIONCell ProliferationMESENCHYMAL TRANSITIONtumorigenesis cancer treatment cancer stem cells miR-205-5p oncogenes breast cancerMICRORNA EXPRESSIONTumor Suppressor ProteinsLapatinibCell BiologyTrastuzumabmedicine.diseaseGENEMicroRNAstumorigenesisDrug Resistance NeoplasmCancer cellQuinazolinesCancer researchNeoplasm Recurrence LocalCarcinogenesisTranscription FactorsCell Death & Disease
researchProduct

Targeting the Cancer Initiating Cell: The Ultimate Target for Cancer Therapy

2012

An area of therapeutic interest in cancer biology and treatment is targeting the cancer stem cell, more appropriately referred to as the cancer initiating cell (CIC). CICs comprise a subset of hierarchically organized, rare cancer cells with the ability to initiate cancer in xenografts in genetically modified murine models. CICs are thought to be responsible for tumor onset, self-renewal/maintenance, mutation accumulation and metastasis. CICs may lay dormant after various cancer therapies which eliminate the more rapidly proliferating bulk cancer (BC) mass. However, CICs may remerge after therapy is discontinued as they may represent cells which were either intrinsically resistant to the or…

PTENgerminal mutationchemotherapeuticmedicine.medical_treatmentAntineoplastic AgentsPI3KTargeted therapyMetastasisMice03 medical and health sciencesTARGETED THERAPY0302 clinical medicineCancer stem cellNeoplasmsradiologicalDrug DiscoverymedicineAnimalsHumansPTENAkt; mTOR; PI3K; PTEN; Targeted therapy; Therapeutic sensitivityPI3K/AKT/mTOR pathway030304 developmental biologyPharmacologyBiological Products0303 health sciencesbiologyAKTMTORAktCD44Wnt signaling pathwayCancertargeted therapymedicine.disease3. Good healththerapeutic sensitivityxenografts030220 oncology & carcinogenesisImmunologymTORNeoplastic Stem CellsCancer researchbiology.proteinCurrent Pharmaceutical Design
researchProduct

Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34⁺ cells in a xenograft model

2012

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), delivered as a membrane-bound molecule expressed on the surface of adenovirus-transduced CD34+ cells (CD34-TRAIL+), was analyzed for its apoptotic activity in vitro on 12 breast cancer cell lines representing estrogen receptor-positive, HER2+ and triple-negative (TN) subtypes and for its effect on tumor growth, vascularization, necrosis, and lung metastasis incidence in NOD/SCID mice xenografted with the TN breast cancer line MDA-MB-231. Mesenchymal TN cell lines, which are the richest in putative tumor stem cells among the different breast cancer cell subtypes, were the most susceptible to apoptosis induced by CD34-TRAIL+ cel…

PathologyCancer ResearchCD34Antigens CD34ApoptosisMice SCIDMetastasisMetastasisTNF-Related Apoptosis-Inducing LigandMicePreclinical StudyMice Inbred NODNeoplasm Metastasisskin and connective tissue diseasesHeterologousTumorbiologyCell DeathCancer stem cellsTumor BurdenOncologyNeoplastic Stem CellsTumor necrosis factor alphaFemalemedicine.medical_specialtyTRAIL BREAST CANCERTransplantation HeterologousBreast NeoplasmsSCIDCell LineTriple-negative breast cancerCancer stem cellCell Line TumormedicineAnimalsHumansAntigensTransplantationCD44Mesenchymal stem cellmedicine.diseaseApoptosisCell culturebiology.proteinCancer researchInbred NODCD34Settore MED/36 - Diagnostica Per Immagini E RadioterapiaAnimals; Antigens CD34; Apoptosis; Breast Neoplasms; Cell Death; Cell Line Tumor; Female; Humans; Mice; Mice Inbred NOD; Mice SCID; Neoplasm Metastasis; Neoplastic Stem Cells; TNF-Related Apoptosis-Inducing Ligand; Transplantation Heterologous; Tumor BurdenmTRAIL
researchProduct

Molecular Profiling of Potential Human Prostate Cancer Stem Cells

2013

We have investigated the expression of Oct-4, Suz-12, and Cripto-1, as presumptive “stemness” genes, and of connexin 43 (Cx43), Cx32 and androgen receptor (AR), as cell differentiation genes, in two human prostate cancer cell lines, PC3 and LNCaP. This aiming to define molecular profiles of prostate cancer stem cells for a better understanding of prostate carcinogenesis and tumor progression, as well as for prognostic or therapeutic purposes. Cells were grown in 3-dimensional (3D) cell cultures to favor clonal expansion of cancer stem and early progenitor cells, and compared to cells grown in 2-dimensional (2D) cell cultures. Under 3D culture conditions, LNCaP cells and PC3 cells generated …

Pathologymedicine.medical_specialtyCellular differentiationBiologymedicine.diseaseProstate cancerTumor progressionCancer stem cellCell cultureLNCaPmedicineCancer researchStem cellProgenitor cellJournal of Stem Cell Research & Therapy
researchProduct

Differentiation of human osteosarcoma 3AB-OS stem-like cells in derivatives of the three primary germ layers as an useful in vitro model to develop s…

2013

A number of solid tumors contain a distinct subpopulation of cells, termed cancer stem cells (CSCs) which represent the source for tissue renewal and hold malignant potential and which would be responsible for therapy resistance. Today, the winning goal in cancer research would be to find drugs to kill both cancer cells and cancer stem cells, while sparing normal cells. Osteosarcoma is an aggressive pediatric tumor of growing bones that, despite surgery and chemotherapy, is prone to relapse. We have recently selected from human osteosarcoma MG63 cells a cancer stem-like cell line (3AB-OS), which has unlimited proliferative potential, high levels of stemness-related markers, and in vivo tumo…

Pathologymedicine.medical_specialtyIn vitro differentiationHuman osteosarcomaCellular differentiationCancerCancer Stem CellBiologymedicine.diseaseStem cell markerEndothelial stem cellCancer stem cellCancer cellmedicineCancer researchOsteosarcomaStem cellPluripotentiality
researchProduct

In Vitro Identification and Characterization of CD133pos Cancer Stem-Like Cells in Anaplastic Thyroid Carcinoma Cell Lines

2008

BackgroundRecent publications suggest that neoplastic initiation and growth are dependent on a small subset of cells, termed cancer stem cells (CSCs). Anaplastic Thyroid Carcinoma (ATC) is a very aggressive solid tumor with poor prognosis, characterized by high dedifferentiation. The existence of CSCs might account for the heterogeneity of ATC lesions. CD133 has been identified as a stem cell marker for normal and cancerous tissues, although its biological function remains unknown.Methodology/principal findingsATC cell lines ARO, KAT-4, KAT-18 and FRO were analyzed for CD133 expression. Flow cytometry showed CD133(pos) cells only in ARO and KAT-4 (64+/-9% and 57+/-12%, respectively). These …

Pathologymedicine.medical_specialtySciencemedicine.medical_treatmentThyroid Nuclear Factor 1Cell Culture TechniquesAntineoplastic AgentsCell SeparationStem cell markerDiabetes and Endocrinology/ThyroidSettore MED/13 - EndocrinologiaAntigens CDThyroid peroxidaseCancer stem cellCell Line TumorBiomarkers TumormedicineHumansANAPLASTIC THYROID CARCINOMA CANCER STEM CELLS CD133AC133 AntigenThyroid NeoplasmsGenetics and Genomics/Cancer GeneticsThyroid cancerTumor Stem Cell AssayCell ProliferationGlycoproteinsOncology/Head and Neck CancersMultidisciplinarybiologyCell growthQCarcinomaRNuclear ProteinsTumor Stem Cell Assaymedicine.diseaseFibronectinsembryonic structuresNeoplastic Stem CellsCancer researchbiology.proteinMedicineThyroglobulinStem cellPeptidesTranscription FactorsResearch ArticlePLoS ONE
researchProduct

Identification of progenitor cancer stem cell in lentigo maligna melanoma.

2008

:  The potential role of stem cells in neoplasia has aroused considerable interest over the past few years. A number of known biologic characteristics of melanomas support the theory that they may originate in a mutated stem cell. Melanocytic stem cell markers have been described recently. Moreover, the CD133 cells that show surface markers for CD34 are stem cells primitive. These stem cells are capable of differentiating into neurons, glia, keratinocytes, smooth muscle cells, and melanocytes in vitro. The identification of cancer stem/initiating cells with a crucial role in tumor formation may open up new pharmacologic perspectives. The purpose of this study is to detect the expression of …

Pathologymedicine.medical_specialtySkin NeoplasmsCD34Antigens CD34DermatologyBiologyStem cell markerHutchinson's Melanotic FreckleCancer stem cellAntigens CDMelanoblastmedicineSettore MED/35 - Malattie Cutanee E VenereeHumansAC133 AntigenLentigo maligna melanomaGlycoproteinsMelanomaGeneral Medicinemedicine.diseasecancer stem cell lentigo maligna melanomaNeoplastic Stem CellsMelanocytesStem cellPeptidesHair FollicleBiomarkersAdult stem cell
researchProduct